XRAY stock sentiment todayDENTSPLY SIRONA Inc.
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
XRAY
DENTSPLY SIRONA Inc.A legacy dental giant currently engulfed in an accounting crisis, management overhaul, and a plummeting share price that suggests deep-seated internal rot.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for XRAY. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by fear and uncertainty following the sudden termination of CEO Simon Campion and CFO Glenn Coleman in late 2024. The market is reacting to a 'restatement of financial statements' and a suspended dividend, leading to a massive sell-off and 'falling knife' technical profile.
- ·SEC investigations and internal accounting probes
- ·Abrupt C-suite departures signaling deeper operational issues
- ·Suspension of quarterly dividends destroying income investor trust
- ·Potential delisting warnings due to delayed financial filings
Financial
Fundamentals are currently untrustworthy due to ongoing audits, but historical data shows stagnant organic growth and shrinking margins. The balance sheet is pressured by high debt-to-equity relative to peers and a lack of free cash flow visibility.
- ·Negative Net Income (TTM) due to massive goodwill impairments
- ·Operating Margin compression from 18% to low single digits
- ·Debt-to-EBITDA ratio significantly higher than 5-year average
- ·Suspended dividend previously yielding ~4.5%
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Quiet accumulation — the chatter is cold but the smart money is leaning in.
- ·Insiders bought a net $516K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Further regulatory fines or sanctions from the SEC
- ·Customer churn to competitors during management instability
- ·Potential breach of debt covenants if earnings are restated significantly lower
- ·Inability to attract top-tier executive talent to steer the turnaround
Peer temperature
How direct competitors stack up against XRAY right now.
- NEUTRALENVXEnvista Holdings Corp
WARMER — While also facing macro headwinds, it lacks XRAY's acute accounting scandals and maintains a cleaner corporate governance profile.
See full analysis → - HOTALGNAlign Technology, Inc.
HOTTER — Dominates the high-growth clear aligner market with superior margins and a robust, transparent balance sheet.
See full analysis → - NEUTRALHSICHenry Schein, Inc.
WARMER — Trading at a reasonable P/E with a much more stable distribution-led business model that avoids XRAY's manufacturing volatility.
See full analysis →
- XRAY-17.4%
- ENVX-22.6%
- ALGN-9.3%
- HSIC+0.2%
Analyst price target
Consensus average of 11 analysts · median 14.00
Source: StockAnalysis.com · updated 2026-08-21
AI-generated analysis for informational purposes only. Not financial advice.